Most of our side-effect write-ups are cautionary. This one is different: urolithin A is one of the few longevity supplements whose safety data actually looks clean. The interesting question isn’t “what goes wrong” — it’s “how confident can we be, given how short the trials were?” For the efficacy side of the ledger, see our urolithin A evidence monograph.
What the human trials found: well tolerated
The safety story starts with a proper first-in-human study. In a randomized, double-blind, placebo-controlled trial in sedentary elderly adults, urolithin A was given as single doses up to 2,000 mg and as 500–1,000 mg per day for 28 days. It was safe and well tolerated, with no serious adverse events and a pharmacokinetic and adverse-event profile that did not differ meaningfully from placebo.[1]That is a stronger safety foundation than almost anything else on the longevity shelf.
The two later muscle RCTs reinforced it. In middle-aged adults, four months of supplementation was reported as safe with no significant excess of adverse events.[2] In a separate trial in older adults, urolithin A up to 1,000 mg per day for four months was again safe and well tolerated, with adverse events comparable to placebo.[3] Across the program, the tolerability finding replicated even where the efficacy findings were modest.
| Trial | Dose & duration | Safety finding |
|---|---|---|
| First-in-human (elderly) | Single doses to 2,000 mg; 500–1,000 mg/day × 28 days | Safe, well tolerated; no serious AEs |
| Middle-aged adults | Up to 1,000 mg/day × 4 months | No significant excess of AEs vs placebo |
| Older adults | Up to 1,000 mg/day × 4 months | Well tolerated; AEs comparable to placebo |
The mild, rare stuff
When adverse events did turn up, they were minor and did not cluster into a pattern. The most commonly mentioned complaints in this class are occasional, mild gastrointestinal effects — the sort of thing you would expect from any oral supplement — and importantly they did not occur at a higher rate than placebo in the controlled trials.[3] No dose-limiting toxicity, no signal on liver or kidney panels, and no serious adverse events attributable to the compound were reported across the human program.[1] The preclinical toxicology backs this up: a formal safety assessment in animals found no adverse effects and supported urolithin A’s recognition as generally safe, the basis for its GRAS (Generally Recognized As Safe) status.[4]
The honest limits
Here is where balance matters. The trials that established this clean profile ran weeks to a few months, not years.[1][3] Mitophagy induction is a biologically active process, and no one has characterized what daily use looks like over the multi-year horizons people actually take longevity supplements for — so long-term safety is unestablished, not proven benign. The trial populations were also relatively healthy adults; effects in people with significant chronic disease are less well studied.
Two more honest caveats. First, drug–supplement interactions are largely unstudied — urolithin A has not been systematically tested against common medications, so “no known interactions” mostly reflects a lack of investigation rather than a clean bill of health. If you take prescription drugs, that gap is worth a conversation with your clinician. Second, it is a supplement, not an approved drug: it hasn’t been through the long-term outcome trials and post-marketing surveillance that would let anyone speak confidently about rare or delayed harms. Staying within studied doses is the sensible move — see our urolithin A dosage guide for what the trials actually used.
The honest bottom line
Urolithin A is genuinely one of the better-tolerated compounds we cover: across a first-in-human safety study and two placebo-controlled RCTs, it was well tolerated with adverse events comparable to placebo, no serious events, and a supporting toxicology package behind its GRAS status.[1][4]The mild reports that exist are occasional and gastrointestinal, not a dose-limiting pattern. The single real caveat is duration: this is a clean short-term record, and multi-year safety plus interactions remain genuinely open questions. Treat it as a low-risk supplement whose safety story is reassuring but incomplete — which is a very different, and more defensible, profile than a peptide like MOTS-c, whose human side-effect data barely exists.